Sight Diagnostics is an Israeli medical devices startup that’s using AI technology to speed up blood testing. Its mission is to change the way blood testing is done by providing fast, convenient and accurate diagnostics in a compact platform designed for use in any clinical setting, overseen by CLIA certified lab. Developed over almost a decade of research, its technology combines the latest innovations in blood sample preparation, optics, chemistry, biology, physics and computer science. Its first product, Parasight™, has diagnosed malaria in nearly 1 million tests across 24 countries. Sight OLO®, their latest blood analyzer, digitizes blood with only 2 drops of a finger prick or venous sample and provides lab-grade CBC results in minutes.

Register for Details

For more details on financing and valuation for Sight Diagnostics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Sight Diagnostics

Forge green plus iconForge green minus icon

What is Sight Diagnostics's IPO price?

The IPO price for Sight Diagnostics will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.
Forge green plus iconForge green minus icon

Can you invest in Sight Diagnostics?

Sight Diagnostics is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell Sight Diagnostics shares pre-IPO?

If you own Sight Diagnostics pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is Sight Diagnostics a publicly traded company?

Sight Diagnostics is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Forge green plus iconForge green minus icon

When was Sight Diagnostics founded?

Sight Diagnostics was founded in 2012.

Who are Sight Diagnostics's major investors?

Koch Disruptive Technologies
OurCrowd
BridgeOne Capital China
Longliv Ventures
Microtech Ventures
ForMED Ventures
Emery Capital
Updated on: Apr 20, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.